129s wlstm1.1lan j

All animals used in this study received humane care in compliance with the principles stated in the Guide for the Care and Use of Laboratory Animals, NIH Publication, 1996 edition, and the protocol was approved by the Institutional Animal Care Committee of University of Washington. The C57BL/6 and SCID/Beige mice were purchased from Charles River (Wilmington, MA). Col1a2-CreER^T2, 129S-Wls^tm1.1Lan/J and B6.Cg-Gt(ROSA)26Sor^{tm3(CAG-EYFP)Hze}/J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were genotyped by polymerase chain reaction using mouse genomic DNA from tail biopsy specimens. The sequences of genotyping primers and the expected band sizes for PCR are listed in Table S1. PCR products were separated electrophoretically on 1% agarose gels and visualized via ethidium bromide under UV light.

Wl floxed mutant mice (129S-Wls^tm1.1Lan/J) were purchased from The Jackson Laboratory (Stock #012888; Bar Harbor, ME). Transgenic mice expressing Cre recombinase under the control of a 2.5-kb fragment of the human podocin promoter were also obtained from The Jackson Laboratory. Mice with podocyte-specific ablation of Wntless were generated by mating Wl floxed mice with podocin-Cre mice at the animal facility of the University of Pittsburgh Medical Center. The mouse model of podocyte injury was established by intravenous injection of ADR as described in the Detailed Methods. All animal studies were performed according to the NIH Guide for the Care and Use of Laboratory Animals and by use of the procedures approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh and the University of Connecticut, School of Medicine.